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ABSTRACT
Background and the purpose of the study: The binding ability of a drug to serum albumin has 
influence on the pharmacokinetics of a drug. In the present study, the mutual interaction of 
anticancer drug erlotinib hydrochloride with bovine serum albumin (BSA) using fluorescence 
and UV/vis spectroscopy was investigated. 
Methods: The BSA solution (0.1 mM) was prepared daily in Tris buffer (0.05 mol l-1, pH =7.4) and 
treated at final concentration of 1.67×10-5 M with different amounts of erlotinib hydrochloride 
to obtain final concentrations of 0, 0.2, 0.4, 0.8, 1, 2, 4, 6, 8, 20 and 42 µM receptively. The 
mixture was allowed to stand for 5 min and the fluorescence quenching spectra were recorded 
at 298, 303, 308 and 313 K.
Results: It was found that erlotinib hydrochloride caused the fluorescence quenching of BSA 
by the formation of a BSA-erlotinib hydrochloride complex. The mechanism of the complex 
formation was then analyzed by determination of the number of binding sites, apparent binding 
constant Ka, and calculation of the corresponding thermodynamic parameters such as the free 
energy (∆G), enthalpy (∆H) and entropy changes (∆S) at different temperatures. Results showed 
that binding of erlotinib hydrochloride to BSA was spontaneous, and the hydrophobic forces 
played a major role in the complex formation. The distance, r, between donor (BSA) and 
acceptor (erlotinib hydrochloride) was found to be less than 8 nm suggesting the occurrence of 
non-radiative energy transferring and static quenching between these two molecules.
Conclusion:  The  results  provided  preliminary  information  on  the  binding  of  erlotinib 
hydrochloride to BSA and the presence of a single binding site on BSA and Ka values for the 
association of BSA with erlotinib hydrochloride increased by the increase in temperature.
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INTRODUCTION
Erlotinib  hydrochloride  (Figure  1)  belongs  to  a 
group of anti cancer drugs known as inhibitors of 
epidermal growth factor receptor (EGFR) tyrosine 
kinase which is highly expressed in different forms 
of cancers. This drug binds to ATP- binding site in 
a  reversible  manner  and  disables  phosphorylating 
ability of the oncogenic EGFR and inhibits signal 
transduction cascade causing apoptosis of malignant 
cells. Erlotinib hydrochloride is used for treatment 
of non-small cell lung cancer, pancreatic, ovarian, 
head and neck cancers(1). Plasma protein binding of 
erlotinib hydrochloride in mouse, rat, and human has 
been evaluated to be 95, 92, and 92%, respectively 
(2).
Serum  albumins  are  the  major  soluble  protein 
constituents  of  the  circulatory  system  possessing 
many  physiological  functions  of  which  the  most 
important are serving as a depot and a transport protein 
for  many  endogenous  and  exogenous  compounds 
such as drugs (3). Bovine serum albumin (BSA), 
due  to  its  structural  similarity  to  human  serum 
albumin (HSA) and considerable stability, has been 
used to replace human serum albumin in protein-
drug studies (2). BSA consists of three homologous 
domains  (I,  II,  III)  and      each  domain  in  turn  is 
the product of two sub-domains (4). BSA has two 
tryptophans residues, Trp–134 and Trp–212, which 
are embedded in the first sub-domain IB and sub-
domain IIA, respectively (3).  The high sensitivity 
of  tryptophan  residues  to  its  local  environment 
produces valuable intrinsic fluorescence properties 
in  BSA  molecule.  Changes  in  emission  spectra 
of tryptophan are common in response to protein 
conformational  transitions,  subunit  association, 
denaturation or substrate binding. 
Since the binding ability of a drug to serum albumin 
may have an important impact on pharmacokinetics 
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was prepared in Tris buffer solution (0.05 mol l-1, 
0.1 mol l-1 NaCl, pH=7.4). The BSA solution (0.1 
mM) was prepared daily in Tris buffer (0.05 mol l-1, 
pH =7.4) and treated at final amounts of 1.67×10-5 M 
with different concentrations of erlotinib solution to 
give concentrations of 0, 0.2, 0.4, 0.8, 1, 2, 4, 6, 8, 20 
and 42 µM respectively. The mixture was allowed 
to stand for 5 min and the fluorescence quenching 
spectra were recorded at 298, 303, 308 and 313 K.
RESULTS  AND  DISCUSSION
 
Fluorescence quenching spectra
The  fluorescence  intensity  of  a  compound  is 
decreased by a variety of molecular interactions such 
as excited-state reactions, molecular rearrangements, 
energy transfer, static, and dynamic quenching (8). 
Such  decrease  in  intensity  is  called  fluorescence 
quenching. Static quenching refers to formation of 
complex  between  quencher  and  the  fluorophore, 
while dynamic quenching refers to the collision of 
the quencher and fluorophore during the excitation 
process.  Using  Stern–Volmer  equation  (Eq.  [1]) 
and  analyzing  the  fluorescence  quenching  data, 
the  fluorescence  quenching  relationship  may  be 
predicted as:
F0 /F = 1 + Kqτ0 [Q] = KSV [Q]                      [1]
where F0 and F are the fluorescence intensities before 
and after addition of the quencher, respectively, Kq, 
KSV, τ0 and [Q] are the quenching rate constant of the 
bimolecular, the Stern–Volmer dynamic quenching 
constant,  the  average  lifetime  of  the  bimolecular 
without  quencher  and  the  concentration  of  the 
quencher, respectively. Equation [1] was applied to 
determine KSV by linear regression of a plot of F0/F 
versus [Q].
Figure 2 shows changes in the fluorescence intensity 
by addition of erlotinib hydrochloride at different 
as well as the determination of the dosage form of 
the drug (5), changes in the intrinsic fluorescence 
intensities  of  BSA-drug  complex  could  provide 
considerable  information  regarding  the  binding 
characteristics and the therapeutic effectiveness of 
drugs (6). 
Although,  the  fluorescence  quenching  study  of 
BSA interactions with many compounds including 
drugs  using  fluorescence  spectroscopy  have  been 
thoroughly investigated and reported (4), to the best 
of our knowledge, the binding profile of erlotinib       
hydrochloride to this class of proteins has never been 
investigated. In this study, the properties of binding 
between  erlotinib  hydrochloride  and  BSA  were 
investigated using fluorescence quenching method 
and UV/vis absorption spectroscopy. The aim of this 
study  was  to  analyze  the  fluorescence  quenching 
mechanism of BSA by erlotinib hydrochloride, the 
number  of  the  biding  sites,  the  specific  binding 
pocket, and the effects of erlotinib hydrochloride on 
the conformational changes of BSA.
MATERIAL  AND METHODS
Material
Erlotinib hydrochloride was synthesized as described 
before (7). BSA was purchased from Sigma-Aldrich 
(Dorset, UK). All other reagents were obtained from 
Merck (Darmstadt, Germany).
Spectral measurements
The UV spectrum was recorded at room temperature 
on  a  Shimadzu  2550  UV/VIS  Spectrophotometer 
(Shimadzu,  Japan)  equipped  with  3.0  cm  quartz 
cells.  All  fluorescence  spectra  were  recorded  on 
RF-5301  Spectrofluorimeter  (Shimadzu,  Japan) 
equipped with a xenon lamp source, a 1.0 cm quartz 
cell  and  a  thermostat  bath.  The  widths  of  both 
excitation and emission slits were set to 5 nm. The 
optimum excitation and emission wavelengths for 
BSA were found to be 295 and 339 nm, respectively. 
The resulting fluorescence data were corrected for 
the background fluorescence of buffer and erlotinib 
hydrochloride. 
Procedures
The stock solution of erlotinib hydrochloride (0.25 mM) 
Fig.1.
Figure 1. Erlotinib hydrochloride.
Fig.2.
7
1
Figure 2. Fluorescence spectra of BSA in the presence of various 
concentrations  of  erlotinib  hydrochloride  in  Tris  buffer  (0.05 
mol l-1, pH =7.4) at 313 K (λem= 339 nm). BSA concentration: 
1.67×10-5 M, the concentration of erlotinib hydrochloride (1→7): 
0, 0.6, 4, 6, 8, 20 and 42 µM.181
concentrations  to  BSA  solutions.  As  it  is  seen, 
presence of erlotinib hydrochloride in BSA solution, 
even at low concentrations, resulted in fluorescence 
quenching of the BSA molecule, and the amount 
of  fluorescence  quenching  was  dependent  on  the 
concentration of erlotinib hydrochloride molecules in 
the BSA solution. At higher erlotinib hydrochloride 
concentrations,  a  slight  blue  shift  was  produced 
indicating intermolecular binding between erlotinib 
hydrochloride and BSA. 
In  order  to  obtain  the  results  within  the  linear 
concentration range, the experiments were carried out 
within the linear part of Stern–Volmer dependence  (F0/F 
versus [Q]). Figure 3 displays the Stern–Volmer plots 
of the quenching of BSA by erlotinib hydrochloride 
at different temperatures.  As it is shown, at low 
concentration of erlotinib hydrochloride, the curves 
have linear relationships, and the slopes increases 
by the increase in temperature, thereby indicating 
the occurrence of a dynamic quenching interaction 
between erlotinib hydrochloride and BSA. Moreover, 
in dynamic quenching, diffusion plays an important 
role and since higher temperatures result in larger 
diffusion  coefficients,  the  bimolecular  quenching 
constants are expected to increase by the increase 
in  temperature.  In  table  1,  the  binding  constants 
obtained by the Stern–Volmer method for erlotinib 
hydrochloride-BSA complex are listed.
In a collisional or dynamic quenching the fluorophore 
and the quencher contact each other during the lifetime 
of the excited state, whereas in a static quenching a 
complex is formed between the fluorophore and the 
quencher. It is possible to distinguish static and dynamic 
quenching through the study of their dependency to 
temperature and viscosity, or by lifetime measurements.
Generally,  the  collisional  quenching  constant  of 
various  kinds  of  quenchers  with  biomolecule  is 
2.0×1010  l  mol−1s−1.  However,  the  rate  constant 
of  the  protein  quenching  initiated  by  erlotinib 
hydrochloride was found to be much greater than the 
maximum collision quenching constant of biomolecule, 
indicating  that  the  quenching  process  is  static.  In 
addition, ground state complex by absorption spectra 
also indicates a static quenching involvement. The 
dynamic  quenching  only  affects  the  excited  state 
of  quenching  molecule  with  no  function  on  the 
absorption spectrum of quenching substances.
Binding constant and binding sites 
The apparent binding constant Ka and binding sites 
n for a small molecule that binds independently to a 
set of equivalent sites on a macromolecule (9) can be 
obtained from the following equation.
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where F0 and F are the fluorescence intensities before 
and after the addition of the quencher, [Q] and [P] 
are the total concentrations of quencher and protein, 
respectively . By plotting log (F0-F)/F versus log (1/ 
([Q] – (F0 – F) [P]/F0)), the number of binding sites, 
n, and binding constant Ka can be obtained.
In the table 2, the binding constants, Ka, and binding 
sites,  n,  for  erlotinib  hydrochloride  associated 
with  BSA  are  listed.  The  correlation  coefficients 
are larger than 0.98 indicating that the interaction 
between erlotinib hydrochloride and BSA is well in 
agreement with the site-binding model underlined 
in Eq. [2]. The Ka values for association of erlotinib 
hydrochloride  with  BSA  increased  by  the  rise  in 
temperature which may indicate the formation of a 
stable complex at higher temperatures (10) and it is 
consistent with the dynamic quenching mechanism 
obtained for the interaction of erlotinib with BSA. 
Dynamic  quenching  which  depends  on  collisions 
between  the  excited  state  and  the  quencher  is  a 
diffusion-controlled  process,  and  increases  with 
Table1. Stern Volmer quenching constant of the systems of Erlotinib hydrochloride-BSA at different temperatures.
pH  T(K) Ksv (Lmol-1) ×10-4   Kq (Lmol-1s-1)×10-12 Ra Regression equation SDb
7.4 298 3.6046 3.6046 0.9810 Y=0.0516x+0.9394 0.0125
303 3.8272 3.8272 0.9840  Y=0.0542x+0.9453  0.0158
308 3.9144 3.9144 0.9928 Y=0.0629x+0.9453 0.0201
313 4.5931 4.5931 0.9940 Y=0.0752x+0.9805 0.0234
a R is the correlation coefficient.
b SD is standard deviation.
pH  T(K) Ka (1mol-1)× 10-4 n ∆H (kJ mol-1)             ∆G (kJ mol-1)            ∆S (J mol-1)
7.4 298 2.9882 1.1165 38.910 -25.838 217.278
303 5.4250 1.2357 -26.924
308 5.6809 1.0457 -28.011
313 6.9838 0.9692 -29.097
Table 2.The binding constant, Ka, the number of binding sites, n, and the thermodynamic parameters for the association of Erlotinib 
hydrochloride with BSA.
([Q] – (F0 – F) [P]/F0)
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temperatures. The obtained values for n were found 
to be ≈ 1 indicating that only a single binding site 
exists in BSA for erlotinib hydrochloride molecules. 
This  number  is  in  agreement  with  the  reported 
numbers (5).
Thermodynamic Parameters and Nature of Binding 
Forces
There  are  essentially  four  types  of  non-covalent 
interactions that play a key role in binding ligand 
to  proteins.  These  are  hydrogen  bonds,  Van  der 
Waals forces, electrostatic and hydrophobic bonds 
interactions (11-13).  The thermodynamic parameters 
dependency to temperature must be obtained in order 
to elucidate the interaction forces between erlotinib 
hydrochloride and BSA.  If the enthalpy change (ΔH) 
over the temperature range under study is minimal, 
then, the thermodynamic parameters ΔS, and ΔG can 
be determined by the Van’t Hoff equation (Eq.[3-5]) 
(12):
                   
ln (K2/K1) = ∆H/R(1/T1-1/T2)          [3]
∆G = -RT lnKa               [4]
∆G = ∆H - T∆S               [5]
where K is the binding constant and R is the gas 
constant.
Enthalpy  change  (∆H),  entropy  change  (∆S) 
and  free  energy  change  (∆G)  for  the  binding 
interaction  between  erlotinib  hydrochloride  and 
BSA  were  calculated  using  Eq.  [3-5]  (9,11-13). 
The thermodynamic parameters for the interaction 
of  erlotinib  hydrochloride  with  BSA  are  shown 
in  table  2.  The  negative  values  of  ∆G  indicate 
that  the  binding  process  is  spontaneous.  The 
enthalpy (∆H) and entropy (∆S) of the interaction 
of  erlotinib  hydrochloride  and  BSA  are  positive. 
According  to  the  report  of  Ross  and  Subramanian 
(12), the positive ΔH and ΔS value is associated with 
hydrophobic interaction, the negative ΔH and ΔS values 
are associated with hydrogen bonding and Van der 
Waals interaction in low dielectric medium. Finally 
very low positive or negative ΔH and positive ΔS 
values are characterized by electrostatic interactions. 
Thus, it is difficult to interpret the thermodynamic 
parameters  of  BSA–  erlotinib  interaction  with  a 
single intermolecular force. Therefore, the binding of 
erlotinib to BSA might involve strong hydrophobic 
interaction as evidenced by the positive values of ΔS 
while electrostatic interaction can not be excluded.
Fluorescence  resonance  energy  transfer  (FRET) 
from BSA to erlotinib hydrochloride 
Fluorescence  resonance  energy  transfer  (FRET) 
is  a  reliable  method  for  studying  protein-ligand 
interactions and evaluation of the distance between 
the ligand and tryptophan residues of the protein.   
The energy transfer efficiency E is defined by the 
following Eq. [6], where r0 is the distance from the 
ligand to the tryptophan residue of the protein, and 
R0 is the Forster critical distance, at which 50% of 
the excitation energy is transferred to the acceptor. R0 
can be calculated from donor emission and acceptor 
absorption  spectra  using  the  Forster  formula  Eq. 
[7].
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In Eq. [7], K
2 is the orientation factor related to the geometry of the donor and 
acceptor of dipoles and K
2 = 2/3 for random orientation as in fluid solution, N is the 
average refractive index of medium in the wavelength range where spectral overlap is 
significant; 
ĭ is the fluorescence quantum yield of the donor; J is the effect of the spectral 
overlap between the emission spectrum of the donor and the absorption spectrum of the 
acceptor,  J  could  be  calculated by Eq.  [8],  where,  F(Ȝ)  is  the  corrected  fluorescence 
intensity  of  the  donor  in  the  wavelength  range  Ȝ  to  Ȝ+¨Ȝ;  İ ( Ȝ)  is  the  extinction 
coefficient of the acceptor at Ȝ. FRET is an important technique to  investigate a variety 
of biological phenomena including energy transfer processes.  
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In Eq. [7], K2 is the orientation factor related to the 
geometry of the donor and acceptor of dipoles and 
K2 = 2/3 for random orientation as in fluid solution, 
N  is  the  average  refractive  index  of  medium  in 
the  wavelength  range  where  spectral  overlap  is 
significant;  Φ  is  the  fluorescence  quantum  yield 
of the donor; J is the effect of the spectral overlap 
between  the  emission  spectrum  of  the  donor  and 
the absorption spectrum of the acceptor, J could be 
calculated by Eq. [8], where, F(λ) is the corrected 
fluorescence intensity of the donor in the wavelength 
range of  λ to λ+∆λ; ε (λ) is the extinction coefficient 
of the acceptor at λ. FRET is an important technique 
to  investigate a variety of biological phenomena 
including energy transfer processes. 
The  spectral  overlap  between  UV/vis  absorption 
spectrum  of  erlotinib  hydrochloride  (acceptor 
fluorophore) and the fluorescence emission spectrum 
of free BSA (donor fluorophore)   is shown in figure 
4. Since the fluorescence emission of protein was 
affected by the excitation light around 288 nm, the 
spectrum ranging from 288 to 488 nm was chosen to 
calculate the overlapping integral. 
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Figure 3. The Stern-Volmer plot for the quenching of BSA by 
erlotinib  hydrochloride  at  298°K(■),  303°K(♦),  308°K(•)  and 
313°K (×). pH 7.40, λex=295 nm and λem=339 nm.
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On the basis of equations 6-8, N= 1.36, and Φ= 0.15 
(8) J was calculated to be 3.89×10-21 cm3 l  mol−1, 
E = 0.36, R0 = 2 nm, and r = 2.20 nm. The average 
distances between a donor and acceptor fluorophore 
is  less  than8  nm,  and  0.5R0  <  r  <  1.5R0  (14) 
suggesting that energy transfer occurs between BSA 
and erlotinib hydrochloride (8). Moreover, since r is 
higher than R0, it suggests that erlotinib hydrochloride 
quench  the  intrinsic  fluorescence  of  BSA  by  non-
radiative energy transference and static quenching.
UV/Vis absorption spectroscopy
The absorption spectra of BSA in the presence and 
absence of erlotinib hydrochloride are illustrated in 
fig. 5. It was observed that the absorbance increased 
by increase in erlotinib hydrochloride concentration 
indicating the formation of a ground state complex. 
As  dynamic  quenching  does  not  affect  the 
absorption spectrum of quenching molecule and it 
only affects the exited states of quenching molecule, 
the  observed  changes  in  BSA  absorbance  in  the 
presence  of  different  concentrations  of  erlotinib 
hydrochloride could be indicative of the occurrence 
of  static  quenching  interaction  between  erlotinib 
hydrochloride and BSA (15). 
 CONCLUSION 
The  experimental  results  suggested  that  erlotinib 
hydrochloride can quench the intrinsic fluorescence 
of BSA through both dynamic and static quenching. 
The  results  also  indicated  that  the  hydrophobic 
interaction  plays  a  major  role  in  stabilization  of 
the  complex.  The  distance  between  BSA  and 
erlotinib hydrochloride was obtained according to 
fluorescence resonance energy transfer. The changes 
of  UV/vis  absorption  spectra  were  indicative  of 
the formation of a ground state complex between 
erlotinib hydrochloride molecules and BSA.
Fig.4.
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Figure  4.  Spectral  overlapping  between  the  UV  absorption 
spectrum  of  erlotinib  hydrochloride  (A)  and  the  fluorescence 
emission of BSA (B).
Figure 5. Absorption spectra of erlotinib hydrochloride, BSA, and 
erlotinib hydrochloride–BSA complex (a→f). BSA concentration 
was  at  2×10-6 mol  l−1.  Erlotinib  hydrochloride  concentrations  in 
erlotinib hydrochloride –BSA complex were 2, 4, 6 and 8 ×10-6 mol l−1.
Fig.5.
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